skip to main content

H.R. 1499: Protecting Consumer Access to Generic Drugs Act of 2019

Call or Write Congress

To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.

The bill’s titles are written by its sponsor.

Sponsor and status

Bobby Rush

Sponsor. Representative for Illinois's 1st congressional district. Democrat.

Read Text »
Last Updated: May 10, 2019
Length: 22 pages
Introduced
Mar 5, 2019
Status

Ordered Reported on Apr 3, 2019

The committees assigned to this bill sent it to the House or Senate as a whole for consideration on April 3, 2019.

Prognosis
2% chance of being enacted according to Skopos Labs (details)
Source

Position statements

What legislators are saying

Rush Legislation to Lower Prescription Drug Prices Passes the House
    — Rep. Bobby Rush [D-IL1] (Sponsor) on May 16, 2019

Pallone Unveils Policy Solutions to Lower Prescription Drug Prices
    — Rep. Frank Pallone [D-NJ6] (Co-sponsor) on Mar 18, 2019

Olson Slams Democrats For Playing Politics With Affordable Prescription Drugs
    — Rep. Pete Olson [R-TX22] on May 16, 2019

More statements at ProPublica Represent...

What stakeholders are saying

Institute for Spending Reform SpendingTracker.org estimates H.R. 1499 will save $544 million through 2029.

History

Mar 5, 2019
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

Mar 13, 2019
 
Considered by Health

A committee held a hearing or business meeting about the bill.

Mar 27, 2019
 
Considered by Health

A committee held a hearing or business meeting about the bill.

Apr 3, 2019
 
Ordered Reported

A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.

May 10, 2019
 
Reported by House Committee on Energy and Commerce

A committee issued a report on the bill, which often provides helpful explanatory background on the issue addressed by the bill and the bill's intentions.

If this bill has further action, the following steps may occur next:
 
Passed House

 
Passed Senate

 
Signed by the President

H.R. 1499 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 1499 — 116th Congress: Protecting Consumer Access to Generic Drugs Act of 2019.” www.GovTrack.us. 2019. October 22, 2019 <https://www.govtrack.us/congress/bills/116/hr1499>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.